SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pierre Borczuk who wrote (56)6/7/1997 8:13:00 AM
From: James Reynolds   of 370
 
Pierre,

Have been following Vion for a while now. The share action is perplexing, stuck around the $4 level. Is the market concerned at the possible need to raise more money in the near future or does the share structure put investors off?

The company appears to have some exciting technology including Promycin in Phase III, novel anti-virals and TAPET, good scientists, experienced management and close ties to Yale. If they can improve their financial situation they will surely deserve a higher rating.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News